Delivering on Discovery
Private Equity
Investing in Biotechnology

Delivering on Discovery examines the underlying
fundamentals of the industry, the state of the
market, the dynamics of private equity investing,
and the composition of the different players.
It analyses the appetite and concerns of institutional
investors in biotech venture funds, looks at fundraising
behaviour, and investigates how successful biotech
companies have raised private equity.
The report also strongly challenges the suggestion
that a bubble has emerged in the venture sector
and identifies the characteristics of the strongest
performers going forward. Delivering on Discovery also includes a directory of 600 investors in
biotechnology companies. Details include investment
strategy, areas of specialisation, geographic
focus, experience and funds under management.

Edition: First
Format: Report & Directory
Pages: 188
ISBN: 1-904620-06-X
Published: July 2002

Buy Report Online
Presentation in Adobe PDF Format: WILL BE E-MAILED
TO YOU.
£100.00 (Click to Buy)
UK customers: 17.5%
VAT will be added to the above price.
EU customers: 17.5% VAT will be added to the above
price where a valid VAT number is not supplied
by you.
Non- EU customers: No VAT will be added to the
above price
NB: Orders can take up
to 5 working days to be processed.
Please note, orders can only
be cancelled if the product has not yet shipped
to you. After products have been dispatched, no
refunds can be given. See below for full terms
and conditions.

Table of Contents
SECTIONS
- Executive Summary
- Introduction
to Biotechnology
- Drivers of the Biotechnology Industry
- The Structure
of the Biotechnology Industry
- Regional Differences in the Biotechnology
Industry
- Sources of Capital
- Private Equity Funds Raised
- Private
Equity Invested in Biotechnology
- Private Equity Investors in Biotechnology
- Exits and Returns Characteristics
- The Private Equity and Venture
Firm Perspective
- The Biotechnology Firm Perspective
- The Limited
Partner Perspective
FIGURES
- AltAssets Markets Dynamic Model: Biotechnology
- Timeline of Key Biotechnology Events
- New Biotech Drug and Vaccine FDA Approvals
- Number of Biotech Products in Phase III Trials,
1997-2001
- The Average of OECD Countries' Life Expectancy
- Growth of Healthcare and Long-term Care Expenditure,
as a Percentage of GDP
- Key Pharmaceutical Mergers, 1998-2000
- Global Pharmaceutical R&D Expenditure,
1990-2000
- Average Cost of Drug Development
- Typical Creation of a Commercial Biotech Firm)
- Number of Biotech Firms in the US
- US Biotech Company Revenues 1993-2001
- The Leading Biotech Products
- Time Taken from Pharmaceutical Testing to
New Drug Approval
- Examples of Leading Biotech Firms within Sub-sectors
- The Process of Bringing a Drug to Market
- Largest Pharma and Biotech Companies by Market
Cap
- Global Breakdown of Biotech Companies
- Largest US and European Biotech Companies
by Market Cap
- Europe's Technology Hotbeds
- Biotech Stock Indices vs Internet
- Amount Raised by Biotech Firms on US Public
Markets
- Amount Raised by Biotech Firms via PIPEs
- US Venture Investment in Biotech, 1996-2001
- Leading Corporate Venturers
- The Number of New Biotech-Pharma Alliances,
1993-2001
- Value of New Biotech Alliances, 1997-Q3 2001
- Biotech Funds in the Market by Fund Target
Size
- Funds Closed in First Half 2002 Relative to
Target
- US Biotech Venture Investment as a Share of
Total VC Investment, 1995-2002
- Number of Investments Into US Biotech and
Average Deal Size
- Funds Invested in Biotech in Europe, 2000-2002
- Number of Investments into European Biotech
and Average Biotech Deal Size
- Types of Biotech Venture Players
- Geographical Breakdown of Biotech Venture
Investors
- General and Specific Strategies of Biotech
Private Equity Firms
- Number of Biotech IPOs in the US and Europe,
1996-2001
- Value of Biotech IPOs in the US, 1996-2001
- Announced Value of Biotech M&A Transactions,
1995-2001
- Announced Number of Biotech M&A Transactions,
1995-2001
- Return Characteristics of Biotech Venture
Capital Funds
- VC Preferences vs. Biotech Firm Preferences
- Limited Partner Concerns about Investing in
Biotechnology
Report Ordering:
Delivery, Terms & Conditions and FAQs.
|